Study guide

Hematologic, Immunologic, and Infection Supportive Care

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Hematologic, Immunologic, and Infection Supportive Care

Key Takeaways Explain This Topic AI

Myelosuppression causes neutropenia, anemia, and thrombocytopenia; nadir is typically 7-14 days after cytotoxic chemotherapy.

A single temperature of 101 F (38.3 C) or higher, or 100.4 F (38.0 C) or higher sustained over one hour, with an ANC below 500 cells/mcL is febrile neutropenia, an emergency requiring cultures and antibiotics within 1 hour of triage.

Transfusion thresholds and growth factors (filgrastim, pegfilgrastim, ESAs) follow orders; the nurse verifies, monitors, and stops transfusions for reactions.

Immune-related adverse events from checkpoint inhibitors, CRS/ICANS from CAR-T and bispecifics, and graft-versus-host disease require pattern recognition and rapid reporting.

Teaching emphasizes early reporting of any fever, hand hygiene, bleeding precautions, and not self-treating with antipyretics or leftover antibiotics.

Last updated: October 2026

  • Hematologic, Immunologic, and Infection Supportive Care
  • Cytopenias, Nadir Timing, and Risk Recognition

Most cytotoxic regimens injure bone marrow. The nadir (lowest blood-count point) typically occurs 7-14 days after treatment, with recovery by day 21-28, which is why the nurse always ties symptoms to the treatment day. Neutropenia raises infection risk, anemia reduces oxygen delivery, and thrombocytopenia raises bleeding risk. Interpret the absolute neutrophil count (ANC) , hemoglobin, platelet count, and their trend, never a single value in isolation. Calculate ANC as: ANC = total WBC x (% segs + % bands) / 100. Classic severity bands appear on the exam:

  • Parameter Mild Moderate Severe / critical
  • ANC (cells/mcL) 1000-1500 500-999 < 500 (profound < 100)
  • Hemoglobin (g/dL) 10-11.9 8-9.9 < 8, or symptomatic
  • Platelets (cells/mcL) 75k-150k 50k-74k < 20k (spontaneous bleed risk)

A neutropenic patient may look well early in sepsis because few neutrophils mean few localizing signs of pus or redness. Teach patients to report any fever exactly as instructed, plus chills, rigors, cough, sore throat, dysuria, diarrhea, line redness, or confusion, and never to delay because the fever is low or because they already took acetaminophen.

Febrile Neutropenia: The High-Yield Emergency

Febrile neutropenia is defined as a single oral temperature of 38.3 C (101 F) or higher , or 38.0 C (100.4 F) or higher sustained one hour, with an ANC below 500 cells/mcL (or expected to fall below it). It is an oncologic emergency. Priority sequence: rapid assessment and vitals, draw blood cultures (peripheral and from each lumen), then administer broad-spectrum empiric antibiotics, ideally within 60 minutes of presentation. Do not wait for the ANC to result before starting the pathway if risk is high.

  • Problem Key assessment Teaching focus
  • Neutropenia Any fever, chills, ANC trend, vitals Call for any fever, hand hygiene, avoid sick contacts

Anemia Dyspnea, dizziness, chest pain, fatigue, pallor Pace activity, change positions slowly, report chest pain

Thrombocytopenia Petechiae, bruising, bleeding, headache, blood in stool/urine Soft toothbrush, no aspirin/NSAIDs, report neuro changes

Transfusion, Growth Factors, and Bleeding Support

Transfusions support symptomatic anemia or low platelets per ordered thresholds (often platelets transfused below ~10k prophylactically, or higher with bleeding or procedures). Nursing duties: verify the product with two clinicians, confirm consent, obtain baseline vitals, stay with the patient for the first 15 minutes, and monitor for reactions, fever, chills, back pain, dyspnea, hypotension, hives, or hemoglobinuria. If a reaction is suspected, stop the transfusion immediately , keep the line open with normal saline, and follow policy.

Growth factors include filgrastim and pegfilgrastim (neutrophils; expect bone pain) and erythropoiesis-stimulating agents for anemia. Bleeding precautions: soft toothbrush, electric razor, no rectal temps or suppositories when platelets are low, fall prevention, and clearance before aspirin, NSAIDs, supplements, or dental work.

Immune-Mediated Toxicities

Checkpoint inhibitors cause immune-related adverse events (irAEs) : pneumonitis, colitis, hepatitis, dermatitis, endocrinopathies, nephritis, and myocarditis, often treated with corticosteroids. CAR-T and bispecific antibodies cause cytokine release syndrome (CRS) (fever, hypotension, hypoxia) and immune effector cell-associated neurotoxicity syndrome (ICANS) (tremor, aphasia, confusion, scored by ICE). Allogeneic transplant recipients develop graft-versus-host disease (GVHD) with rash, diarrhea, and liver abnormalities.

The OCN priority across all of these is early recognition and escalation, because immunosuppressed and lymphocyte-depleted patients may present with only weakness, confusion, or low appetite before obvious fever. Reassess after each intervention: did fever resolve, were cultures drawn before antibiotics, did the transfusion improve dyspnea, and does the patient understand the next fever plan?

Infection Prevention and Protective Measures

Prevention is as testable as treatment. Hand hygiene is the single most effective measure and is taught to patients, families, and staff. During profound neutropenia some centers add a neutropenic (low-microbial) diet or protective environment, but practices vary, so the nurse teaches the specific plan the oncology or transplant team ordered rather than generic restrictions. Common-sense teaching includes avoiding crowds and sick contacts, daily oral care with a soft brush, perineal hygiene, prompt skin and wound care, and avoiding gardening, pet waste, and standing water without protection.

Live vaccines are generally avoided during active immunosuppression, and the nurse confirms timing with the provider. Patients should not delay reporting any fever for any reason, including embarrassment, a low reading, or self-treatment with acetaminophen, which can mask the very sign the team needs.

Anemia and Thrombocytopenia in Daily Practice

Symptomatic anemia is managed by treating the cause, transfusing per threshold, and teaching energy conservation; the nurse advises changing positions slowly to limit orthostatic dizziness and reporting chest pain, marked dyspnea, or syncope, which suggest the heart is compensating poorly. Erythropoiesis-stimulating agents are used cautiously because of thrombosis and tumor-progression concerns and are not first-line for all anemia.

For thrombocytopenia, the nurse layers precautions to the count: routine caution below 100,000, active bleeding precautions below 50,000, and spontaneous-bleeding vigilance below 20,000, with platelet transfusion often considered prophylactically near 10,000 or earlier with fever or procedures. The nurse holds invasive procedures, avoids intramuscular injections when possible, applies prolonged pressure to puncture sites, and watches for the most dangerous bleed, intracranial hemorrhage, by checking for new severe headache, vision change, or altered mental status.

Connecting each precaution to its specific count and clinical trigger is exactly the reasoning OCN items test.